Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.

Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T

Journal of the European Academy of Dermatology and Venereology : JEADV20 Aug 2014Cited by 70 (Europe PMC)

PMID25139195DOI10.1111/jdv.12629PepBankPUB-25139195

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In glucose-tolerant obese adults with plaque psoriasis, liraglutide did not significantly change PASI compared with placebo after 8 weeks.
In plain wordsIn obese adults with psoriasis, liraglutide did not improve psoriasis severity more than placebo after 8 weeks.
Peptide
Liraglutide
Outcome
No significant changePASI change at 8 weeks
Study
n = 20
Comparator
Placebo
Analysis
Primary
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Measurements
PASI change
−2.6 points
liraglutide
PASI change
−1.3 points
placebo
Source sentences
Summary
After 8 weeks of treatment, no significant change in PASI was found in the liraglutide group (mean±standard deviation: -2.6 ± 2.1) compared with the placebo group (-1.3 ± 2.4) (P = 0.228).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919501
02HumanRandomized controlled trialEfficacy outcome
In glucose-tolerant obese adults with plaque psoriasis, liraglutide did not change the dermatology life quality index compared with placebo.
In plain wordsIn obese adults with psoriasis, liraglutide did not improve skin-related quality of life more than placebo.
Peptide
Liraglutide
Outcome
No significant changeDLQI change
Study
n = 20
Comparator
Placebo
Analysis
Primary
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Measurements
DLQI change
−2.5 points
liraglutide
DLQI change
−3.7 points
placebo
Source sentences
Summary
No difference in DLQI was observed between the groups [-2.5 ± 4.4 (liraglutide) vs. -3.7 ± 4.8 (placebo); P = 0.564].
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919502
03HumanRandomized controlled trialEfficacy outcome
In glucose-tolerant obese adults with plaque psoriasis, hsCRP did not change in either the liraglutide or placebo group.
In plain wordsIn obese adults with psoriasis, the inflammation marker CRP did not change with liraglutide or placebo.
Peptide
Liraglutide
Outcome
No significant changeHigh-sensitivity C-reactive protein
Study
n = 20
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Measurements
hsCRP change
0.25
liraglutide
hsCRP change
0.26
placebo
Source sentences
Summary
HsCRP did not change in any of the groups (0.26 ± 1 (placebo) vs. 0.25 ± 2.2 (liraglutide); P = 0.992).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919503
04HumanRandomized controlled trialEfficacy outcome
In glucose-tolerant obese adults with plaque psoriasis, liraglutide caused more body weight loss than placebo over 8 weeks.
In plain wordsIn obese adults with psoriasis, liraglutide led to more weight loss than placebo over 8 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 20
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Body weight loss
4.7 kg
liraglutide
Body weight loss
1.6 kg
placebo
Source sentences
Summary
Liraglutide treatment resulted in a bodyweight loss of 4.7 ± 2.5 kg compared with 1.6 ± 2.7 kg in the placebo group (P = 0.014)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919504
05HumanRandomized controlled trialSafety outcome
In glucose-tolerant obese adults with plaque psoriasis, no serious adverse events occurred during the 8-week observation period.
In plain wordsIn obese adults with psoriasis, no serious side effects occurred during 8 weeks.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n = 20
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
No serious adverse events occurred during the 8-week observation period.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919506
06HumanRandomized controlled trialSafety outcome
In glucose-tolerant obese adults with plaque psoriasis, transient nausea occurred in 45% of liraglutide-treated patients and in none of the placebo group.
In plain wordsIn obese adults with psoriasis, 45% of liraglutide users had short-term nausea, and none of the placebo group did.
Peptide
Liraglutide
Outcome
IncreaseTransient nausea
Study
n = 20
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Nausea incidence
45%
liraglutide
Source sentences
Summary
The most common complaint was transient nausea, which occurred in 45% of the liraglutide-treated patients but in none from the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919507
07HumanRandomized controlled trialEfficacy outcome
In glucose-tolerant obese adults with plaque psoriasis, liraglutide treatment was accompanied by decreased cholesterol levels.
In plain wordsIn obese adults with psoriasis, cholesterol levels fell with liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseCholesterol levels
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
accompanied by decreased cholesterol levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.
Report a problemFND-2513919505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.